The role of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
Sayenko Ya., Nagybyn V., Mankovsky B.
Modern pharmacology offers a wide range of antidiabetic medications. Among them, very important medications are those that affect the activity of incretins (groups of metabolic hormone-like substances that are released after eating and perform the function of reducing the level of glucose in the blood). This group includes two main classes of substances with a proven therapeutic effect in type 2 diabetes: agonists of incretin receptors, primarily glucagon-like peptide 1, and inhibitors of incretin-destroying enzymes, the main representatives of which are dipeptidyl-peptidase inhibitors 4 (DPP-4). Many studies have convincingly demonstrated that DPP-4 inhibitors have, in addition to antidiabetic, endothelioprotective, capillary stabilizing effects and other spectrums of therapeutic activity, which, by the way, are not only related to mechanisms mediated by glucagon-like peptide-1. In the latest joint consensus of the American Diabetes Association and the European Association for the Study of Diabetes on the management of hyperglycemia in patients with type 2 diabetes, DPP-4 inhibitors are a potent and safe group of oral glucose-lowering drugs that can be used in both patients without cardiovascular and renal pathology, as well as as part of combined therapy with agonists of glucagon-like peptide-1 and inhibitors of sodium-glucose cotransporter 2.
Key words: type 2 diabetes, dipeptidyl-peptidase inhibitors 4, agonists glucagon-like peptide-1, inhibitors of sodium-glucose cotransporter 2.